| September 12, 2005 |
| May 16, 2008 |
| June 1999 |
| December 2008 (final data collection date for primary outcome measure) |
| This protocol has a specific aim of determining whether prior caffeine administration affects the sensitivity and specificity of adenosine perfusion scintigraphy for detection of impaired coronary vascular reserve. [ Time Frame: Assessment is made at the time of research adenosine perfusion scintigraphy ] [ Designated as safety issue: No ] |
| This protocol has a specific aim of determining whether prior caffeine administration affects the sensitivity and specificity of adenosine perfusion scintigraphy for detection of impaired coronary vascular reserve. |
| Complete list of historical versions of study NCT00205166 on ClinicalTrials.gov Archive Site |
| determination of caffeine levels in patients instructed to hold caffeine prior to adenosine imaging [ Time Frame: Assess at time of lab sample results obtained ] [ Designated as safety issue: No ] |
| determination of caffeine levels in patinets instructed to hol caffiene prior to adenosine imaging |
| |
| Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans? |
| Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans? |
We are studying the affect of caffeine on the sensitivity of detecting coronary artery disease (blockages in the blood flow to the heart) with adenosine tracer scans. Adenosine is a drug used routinely in patients to relax heart blood vessels in order to assess for the presence of coronary artery disease. Often, if patients have had caffeine, the adenosine scan is not used because of the belief that caffeine may reduce the ability to detect coronary artery disease. We would like to test whether caffeine affects our ability to detect coronary artery disease with adenosine tracer scanning. We will perform an imaging study of the heart with adenosine after you have received caffeine. |
| |
| |
| Interventional |
| Diagnostic, Randomized, Open Label, Active Control, Parallel Assignment |
| Coronary Artery Disease |
- Procedure: Cardiac SPECT imaging Rest and Stress
- Drug: Caffeine
|
- Active Comparator: Caffeine 400 mg PO 1 hour before adenosine infusion
- Active Comparator: Caffeine 200 mg po one hour before adenosine infusion
|
| |
| |
| Suspended |
| 50 |
| December 2008 |
| December 2008 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Patients who have already completed rest/stress 99mTc sestamibi or 99mTc tetrafosmin imaging will be given a form describing this protocol and asked to volunteer for the additional scan
Exclusion Criteria:
- history of asthma, bronchospastic COPD, or renal failure
|
| Both |
| 18 Years to 80 Years |
| No |
| Contact information is only displayed when the study is recruiting subjects |
| United States |
| |
| NCT00205166 |
| Charles K. Stone, MD, University of Wisconsin |
| 1999-109 |
| University of Wisconsin, Madison |
| Astellas Pharma US, Inc. |
| Principal Investigator: |
Charles K Stone, MD |
Univeristy of Wisconsin |
|
|
| University of Wisconsin, Madison |
| May 2008 |
